Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment Apr 13, 2022
Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic Apr 6, 2022
Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office Mar 22, 2022
Propanc Biopharma’s CEO Believes Proenzyme Therapy May Become the Healthcare Solution of Choice for Treating Cancerous Solid Tumors Mar 16, 2022
Propanc Biopharma’s Cancer Stem Cell Technology Offers Renewed Hope to Achieve a Total Victory Against Metastatic Cancer Mar 2, 2022
Propanc Biopharma’s Joint Research Partnership with the Universities of Jaén and Granada Enters 13th Year Feb 23, 2022
Propanc Biopharma Demonstrates Significant Effects of Proenzyme Therapy on the Tumor Microenvironment Dec 21, 2021
Propanc Biopharma Enters into $5 Million Equity Purchase Facility with Dutchess Capital Growth Fund LP Dec 14, 2021
Propanc Biopharma Appoints Paul Patrizio as Strategic Advisor to Establish US Based R&D Operating Subsidiary, Cellmed Bio LLC, in New Jersey Nov 3, 2021
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes May 17, 2021